Ayvakit (Avapritinib) Patent Expiration, LOE Window & CMS Spending

Ayvakit (Avapritinib) by Blueprint Medicines: FDA Orange Book core substance LOE 2040-04-10 (last listed 2042-03-08), 0 AB generics, $186.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBlueprint Medicines
FDA Application & PathwayN212608 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-04-10
Last Listed Patent or Exclusivity Date2042-03-08
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$186.9M
2024 Medicare Part D Spend$160.0M
2024 Medicaid Spend$26.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel